Israel Secondary Fund (ISF)
Israel Secondary Fund (ISF) is a company that specializes in acquiring interests in Israel-related funds and private companies from various stakeholders such as investors, founders, and employees. With a history dating back to the inception of the secondary market in Israel in 1998, ISF's partners have been involved in numerous transactions within the Venture Capital and Private Equity community. They offer tailored solutions for Limited Partners positions, Secondary Direct acquisitions, and Structured Secondaries, providing additional capital and risk reduction options for funds and investors. ISF prides itself on its creative, discreet, and straightforward approach, prioritizing long-term partnerships and growth opportunities in collaboration with a wide range of PE and VC funds in Israel and internationally. Their investment professionals bring extensive experience in secondary transactions and venture capital, forming close relationships with key industry players to deliver value to all stakeholders involved.
Top Stages
4 past transactions
V-Wave
Series C in 2021
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.
V-Wave
Series C in 2020
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.
Eyeview
Venture Round in 2018
Eyeview Inc., founded in 2007 and based in New York, is a video advertising technology company that specializes in delivering return on investment (ROI) for brands through personalized video advertising. The company's flagship product, VideoIQ, is a comprehensive platform that integrates consumer, brand, and retail data into a decision engine to programmatically deliver one-to-one personalized video ads across various devices including television, desktop, tablet, and mobile. Eyeview's solutions cater to multiple industries, offering lead generation for automotive brands, in-store marketing for CPG and shopper marketers, sales driving tools for retailers, and online booking solutions for travel marketers. The company serves top-tier brands such as P&G, Walgreens, Lowe's, Honda, BMW, and Priceline, with offices strategically located in major cities including Los Angeles, Detroit, Seattle, Chicago, and London.
V-Wave
Series C in 2018
V-Wave Ltd. is a medical technology company specializing in the development of percutaneous implantable therapeutic devices for patients with chronic heart failure. Established in 2009 and headquartered in Caesarea, Israel, with additional offices in the United States, V-Wave aims to address the needs of patients who continue to experience severe symptoms or require hospitalization despite optimal medical treatment. The company's flagship product is the V-Wave Shunt, a biocompatible, inter-atrial unidirectional implant designed to alleviate symptoms related to chronic heart failure by regulating Left Atrial Pressure. This innovative device seeks to improve patients' quality of life by reducing hospitalizations, enhancing exercise capacity, and ultimately providing symptomatic relief. V-Wave's team comprises experienced engineers and medical scientists dedicated to advancing the field of cardiovascular devices.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.